Regeneron's Eylea Quarterly Sales Drop Below $1B for First Time in 8 Years Amid Competition and Shift to High-Dose Version

on

Regeneron's quarterly sales of Eylea have dropped below $1 billion for the first time in 8 years due to regulatory delays, competitive pressure, patient shift to high-dose Eylea HD, and use of cheaper alternatives.3

In Q4, Eylea sales declined 52% while Eylea HD sales rose 66%, offsetting some losses with higher volumes but lower pricing.1

Regeneron Q4 revenue increased 3% to $3.88 billion, beating expectations, with non-GAAP EPS at $11.44 vs. $10.74 forecast; Sanofi collaboration revenue up 35% from Dupixent.1

Total FY 2025 revenue grew only 1% to $14.3B, impacted by Eylea decline.4

Sources:

1. https://stocktwits.com/news-articles/markets/equity/regn-stock-slips-regeneron-earnings-q4-eylea-hd-revenue/cmySjWfR4S5

3. https://www.fiercepharma.com/pharma/regenerons-quarterly-sales-eylea-drop-below-1b-first-time-8-years

4. https://liangchang.substack.com/p/20-global-pharma-q4-2025-earnings